<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997906</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000657121</org_study_id>
    <secondary_id>SINGAPORE-NCC0901</secondary_id>
    <nct_id>NCT00997906</nct_id>
  </id_info>
  <brief_title>Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC</brief_title>
  <official_title>A Randomised Phase II/III Study of Concurrent Cisplatin-Radiotherapy With or Without Induction Chemotherapy Using Gemcitabine, Carboplatin and Paclitaxel in Locally Advanced Nasopharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin, gemcitabine hydrochloride,&#xD;
      carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either&#xD;
      by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy&#xD;
      x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy my kill more&#xD;
      tumor cells. It is not yet known whether giving cisplatin together with radiation therapy is&#xD;
      more effective with or without gemcitabine hydrochloride, carboplatin, and paclitaxel in&#xD;
      treating patients with nasopharyngeal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II/III trial is studying how well giving cisplatin together&#xD;
      with radiation therapy works compared with giving cisplatin and radiation therapy together&#xD;
      with gemcitabine hydrochloride, carboplatin, and paclitaxel in treating patients with locally&#xD;
      advanced nasopharyngeal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the 5-year overall survival of patients with locally advanced nasopharyngeal&#xD;
           cancer treated with concurrent cisplatin and radiotherapy with vs without induction&#xD;
           chemotherapy comprising gemcitabine hydrochloride, carboplatin, and paclitaxel.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess and compare the disease-free survival, distant metastases rate, toxicities,&#xD;
           and quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: Patients are stratified by N-stage (N0-1 vs N2-3) and are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo&#xD;
           intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a&#xD;
           total of 33 fractions).&#xD;
&#xD;
        -  Arm II: Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV&#xD;
           over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and&#xD;
           8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the&#xD;
           last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy&#xD;
           as in arm I.&#xD;
&#xD;
      Quality of life is assessed periodically.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months for 1 year, every 4&#xD;
      months for 1 year, every 6 months for 2 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2009</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at 5 years</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metastases-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor recurrence</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to the Common Toxicity Criteria</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the EORTC QLQ-C30</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin,</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Given once daily 5 days a week for 6½ weeks.</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patients are eligible for inclusion if all of the following criteria are fulfilled:&#xD;
&#xD;
          1. Have given written informed consent, with the understanding that consent may be&#xD;
             withdrawn at any time without prejudice.&#xD;
&#xD;
          2. Loco-regional advanced NPC UICC (1997) Stages T3 - 4 any N, or any Stage T, N2 - 3.&#xD;
&#xD;
          3. A histological diagnosis of WHO Type II or III NPC must have been established at some&#xD;
             time and the investigator must review and confirm the diagnosis prior to&#xD;
             randomization.&#xD;
&#xD;
          4. No evidence of distant metastases in staging work up (including lung, liver and bone&#xD;
             imaging).&#xD;
&#xD;
          5. Cross sectional imaging of the primary and neck disease (MRI preferred)&#xD;
&#xD;
          6. Evaluable disease must be present.&#xD;
&#xD;
          7. Performance status of ECOG grade 0 or 1 (see Appendix I).&#xD;
&#xD;
          8. No prior tumour therapy&#xD;
&#xD;
          9. Adequate bone marrow, renal and hepatic function:&#xD;
&#xD;
             Bone marrow : WBC &gt; 3000 / mm3 (ANC &gt; 1500 / mm3 ),&#xD;
&#xD;
               -  Platelets &gt; 100 000 / mm3,&#xD;
&#xD;
               -  Hb &gt; 10 gm/dl Renal : serum creatinine within institutional normal range (or)&#xD;
                  lower than the lower limit of institutional normal range&#xD;
&#xD;
               -  calculated creatinine clearance &gt; 50 ml / min Hepatic : enzymes (SAP, SGOT) &lt; 2x&#xD;
                  normal&#xD;
&#xD;
               -  bilirubin &lt; 24 µmol / l.&#xD;
&#xD;
         10. At least 18 years of age, of either sex.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patients are to be excluded from the study if any of the following criteria is fulfilled:&#xD;
&#xD;
          1. Uncontrolled hypercalcaemia: calcium ≥ 2.7 mmol/L (10.8 mg/dL).&#xD;
&#xD;
          2. Second primary malignancy (except in situ carcinoma of the cervix or adequately&#xD;
             treated basal cell carcinoma of the skin).&#xD;
&#xD;
          3. Other serious concomitant systemic disorders incompatible with the study (at the&#xD;
             discretion of the investigator).&#xD;
&#xD;
          4. Have serious active infection.&#xD;
&#xD;
          5. Hepatitis B carrier&#xD;
&#xD;
          6. Prior treatment including chemotherapy or radiotherapy.&#xD;
&#xD;
          7. Pregnant or lactating female subjects and subjects with reproductive potential not&#xD;
             implementing adequate contraceptive measures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terence Tan, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Centre - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 17, 2009</study_first_submitted>
  <study_first_submitted_qc>October 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Centre, Singapore</investigator_affiliation>
    <investigator_full_name>Terence Tan Wee Kiat</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

